Renaissance Capital logo

KURA News

US IPO Weekly Recap: All best-efforts and uplistings

KURA

The only deals to get done this week were uplisted or completed on a best-efforts basis. Although there were originally six IPOs on the calendar for this week, only Kura Oncology, First Guaranty Bancshares and Fuling Global were able to get their deals done. Xtera Communications (XCOM)...read more

Cancer biotech Kura Oncology prices Nasdaq IPO at $8

KURA

Kura Oncology, which is developing in-licensed protein inhibitors for solid tumors and blood cancers, raised $50 million by offering 6.25 million shares at $8 per share. The biotech, which is uplisting from the OTCQB (symbol: KURO), had last filed to raise $60 million by offering 3.75 million shares at its then-traded price of $16. Kura Oncology plans to list on the Nasdaq under the...read more

Week ahead: Two biotechs and a tech company

XCOM

In the last week of October, no companies filed for an IPO. October was a difficult month for IPOs: 16 companies went public, pricing an average of 22% below their midpoint. Despite the massive valuation cuts, the average IPO return was just 3.4%, while the return on the S&P 500...read more

Cancer biotech Kura Oncology sets terms for $60 million Nasdaq IPO

KURA

Kura Oncology, which is developing protein inhibitor therapies for solid tumors and blood cancers, announced terms for its IPO on Wednesday. The La Jolla, CA-based company plans to raise $60 million, which would equate to an offering of 3.75 million shares at its current price of $16 on the OTCQB (symbol: KURO). At the proposed price, Kura Oncology would command a fully diluted...read more